Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Pharming Sees 21% Q3 Revenue, Raises 2026 Guidance to $380-390m

Oct 22, 2026, 1:12 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Q3 revenue growth and a tighter, albeit higher, full-year guidance commonly support multiple expansion and positive sentiment. Historically, biotech/pharma names with beat-like prints and raised guidance can see 2-10% intraday moves, contingent on macro tone and pipeline visibility.

AI summary

What happened, with direct paths to the underlying reporting

Pharming reported Q3 2026 revenue of about $117.6 million, up 21% year over year, with operating expenses around $74.6 million, in line with 2025. It tightened 2026 revenue guidance to $380-390 million from $375-395 million, and moved the full results to October 27, 2026. The company continues to focus on rare immune and genetic diseases.

Q3 2026 revenue up 21% to about $117.6m; opex $74.6m.
Guidance tightened: 2026 revenue now $380-390m.
Results update moved forward to Oct 27, 2026.
Pharming focuses on rare immune/genetic diseases.
Conference call: 13:30 CET / 08:30 EDT.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.